Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19

    NEXT STORY
    Laidlaw Venture Partners Continues Strategic Growth with Addition of Paul Korner, MD, MBA and Tony N. Hodges MD FCCP FACP, to its Investment and Operations Committee
    PREV STORY
    Global Microbial Identification Market (2020 to 2025) – Bioterrorism Surveillance Presents Opportunities
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States

    REDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (NASDAQ:RLYP), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Trinity Biotech announces Quarter 4 and Fiscal Year 2017 Financial Results

    DUBLIN, Ireland , March 07, 2018 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a ...

    author_avatar
    NASDAQ Market News

    Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly

    SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease ...

    author_avatar
    NASDAQ Market News